ClinicalTrials.gg
Drug

Alirocumab clinical trials

Also written Praluent, REGN727 and SAR236553.

studies test it
78
open now
8
in phase 3
30
first study started
2009

How each study uses alirocumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the alirocumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
24 Jul 2015 · PRALUENT · BLA 125559 (FDA, Drugs@FDA)
European Union
23 Sept 2015 · Praluent · EMEA/H/C/003882 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Alirocumab
55
alirocumab SAR236553 (REGN727)
10
REGN727/SAR236553
5

Brand

Praluent
34

Development codes

REGN727
27
SAR236553
25

Studies by the year they started

78 studies that test it; most in 2012 (14)

Studies that test alirocumab, by start year
YearStudies
20091
20102
20117
201214
20136
20141
20154
20167
20178
20188
20195
20203
20212
20221
20234
20241
20264

Who runs them

Industry 48 · Other 30

Sanofi (30) · Regeneron Pharmaceuticals (16) · Middle East North Africa Stroke and Interventional Neurotherapies Organization (2) · University Medical Centre Ljubljana (2) · Kobe University (2) · Duke University (1) · Chang Gung Memorial Hospital (1) · University of California, San Francisco (1)

Often tested with

Tested in the same studies.

Ezetimibe (4) · Evolocumab (3) · Atorvastatin (3) · Cholestyramine Resin (3) · Niacin (3) · Fenofibrate (3) · Omega-3 fatty acid (3) · Rosuvastatin (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test alirocumab.

Studies

Open first, then newest update. How each study uses alirocumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 78

See all 78 studies that test alirocumab →

Given beside what is tested · 3 — alirocumab is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with alirocumab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call alirocumab · ClinicalTrials.gg INT006016

  • MeSH (NLM) C571059alirocumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) PP0SHH6V16ALIROCUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1659152Confirmed FDA, Wikidata
  • Wikidata Q4726914alirocumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174849AlirocumabOne source FDA
  • DrugBank DB09302One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.